retatrutide clinical trial duration Eli Lilly's Phase 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments VisualAbstract: Retatrutide reduces body weight

Engages FOXO transcription factor signaling networks: FOXO transcription factors regulate oxidative stress resistance, metabolic adaptation, and longevity-associated gene expression

It refers to a method of administering saline solution fluids, vitamin infusions or nutrients directly into your bloodstream for maximum absorption using a needle or small tube inserted into the vein

The takeaway This new VA research adds to a growing body of evidence: GLP-1s arent just about weight loss theyre reshaping what long-term health can look like

doi:10.1016/0010-7824(95)00189-h Sims J, Lutz E, Wallace K, Kassahun-Yimer W, Ngwudike C, Shwayder J